Transporters and drug therapy: Implications for drug disposition and disease

被引:338
作者
Ho, RH
Kim, RB
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pediat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.clpt.2005.05.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response. Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process. However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play critical roles in the overall disposition of numerous drugs in clinical use. In addition to their roles in xenobiotic transport, drug transporters often mediate important physiologic functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are critical for maintenance of normal homeostasis. In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clinical implications of transporters to drug-drug interactions and subsequent development of adverse effects, inter-individual variability in drug response, and human disease.
引用
收藏
页码:260 / 277
页数:18
相关论文
共 148 条
  • [31] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Fellay, J
    Marzolini, C
    Meaden, ER
    Back, DJ
    Buclin, T
    Chave, JP
    Decosterd, LA
    Furrer, H
    Opravil, M
    Pantaleo, G
    Retelska, D
    Ruiz, L
    Schinkel, AH
    Vernazza, P
    Eap, CB
    Telenti, A
    [J]. LANCET, 2002, 359 (9300) : 30 - 36
  • [32] Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I
    Fitzgerald, ML
    Morris, AL
    Rhee, JS
    Andersson, LP
    Mendez, AJ
    Freeman, MW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (36) : 33178 - 33187
  • [33] Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population
    Frikke-Schmidt, R
    Nordestgaard, BG
    Jensen, GB
    Tybjaerg-Hansen, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (09) : 1343 - 1353
  • [34] Inhibition of P-glycoprotein-mediated drug transport - A unifying mechanism to explain the interaction between digoxin and quinidine
    Fromm, MF
    Kim, RB
    Stein, CM
    Wilkinson, GR
    Roden, DM
    [J]. CIRCULATION, 1999, 99 (04) : 552 - 557
  • [35] Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat
    Funk, C
    Ponelle, C
    Scheuermann, G
    Pantze, M
    [J]. MOLECULAR PHARMACOLOGY, 2001, 59 (03) : 627 - 635
  • [36] Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain
    Gao, P
    Stieger, B
    Noé, B
    Fritschy, JM
    Meier, PJ
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1999, 47 (10) : 1255 - 1263
  • [37] Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin
    Geick, A
    Eichelbaum, M
    Burk, O
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) : 14581 - 14587
  • [38] The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver
    Gerloff, T
    Stieger, B
    Hagenbuch, B
    Madon, J
    Landmann, L
    Roth, J
    Hofmann, AF
    Meier, PJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) : 10046 - 10050
  • [39] GLOMSET JA, 1968, J LIPID RES, V9, P155
  • [40] Goodwin B, 2001, MOL PHARMACOL, V60, P427